Tetra Bio-Pharma and Ovensa Will Engage in a Collaboration to Tackle Brain Cancer

April 11, 2019

OTTAWA, ONTARIO, APRIL 11th, 2019 (GLOBE NEWSWIRE) — Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX-V: TBP) (OTCQB: TBPMF), today announced that it has entered into a collaboration agreement with Ovensa Inc. (“Ovensa”) to evaluate TRIOZAN™, a proprietary nanomedicine platform for targeted delivery of cannabinoids to brain tumor cells.

> View full press release

Ovensa Collaborates with Takeda to Deliver an Antibody to the Brain

March 21, 2019

AURORA, MARCH 21, 2019 – Ovensa Inc. (“Ovensa”) is pleased to announce that it has entered into a collaboration agreement with Takeda Pharmaceutical Company Limited (“Takeda”) to evaluate Ovensa’s proprietary nanomedicine platform called TRIOZAN™ for the delivery of an antibody to the brain and evaluate its performance in a CNS disease model.

> View full press release

$1.38 million in financing for Ovensa

September 12, 2017

MONTREAL, SEPTEMBER 12, 2017 Twenty-two members of Anges Québec, Anges Québec Capital, and Aligo Innovation today announced a major joint investment in Ovensa, the company behind an innovative technology enabling the targeted delivery of therapeutic molecules.

> View full press release

Ovensa Inc. appoints Neil Klompas to its Board of Directors

February 3, 2017

AURORA, ONTARIO, February 3, 2017 – Ovensa Inc., a preclinical stage company that capitalizes on its proprietary TRIOZAN™ Nanomedicine Delivery Platform to improve drugs’ efficacy and safety profile, announces that Mr. Neil Klompas, has been appointed to Ovensa’s Board of Directors.

> View full press release

Anges Québec members contribute to $530,000 investment in Ovensa

June 8, 2016

MONTREAL, June 8, 2016 /CNW Telbec/ – Today Anges Québec announced its members are taking a stake in Ovensa, a biotechnology company. Members of Anges Québec and Aligo Innovation are joining with private investors to inject $530,000 into this Ontario firm, whose new technology delivers therapeutic molecules through oral administration to targeted human tissue, including the brain—a major medical advance.

> View full press release

Aligo grants a licence to Ovensa for the production and marketing of a derivative of chitosan for high-value applications

January 12, 2015

MONTREAL, Jan. 12, 2015 /CNW Telbec/ – Aligo is proud to announce the granting of a worldwide exclusive license for all applications to Ovensa Inc. for the production and commercialization of trimethyl chitosan (TMC), a derivative of chitosan, a technology emanating from the University du Québec à Rimouski (UQAR). TMC was developed by Professor Jonathan Gagnon, chemistry professor from the Department of Biology, Chemistry and Geography, UQAR. Prof. Gagnon is a specialist in the purification, characterization and modification of polysaccharides from natural sources.

> View full press release

SOCPRA concludes a new partnership with Ovensa for marketing chitosan with high added value

November 25, 2013

Sherbrooke, November 25, 2013 – SOCPRA is proud to announce a new licence agreement concluded on August 13, 2013 with Ovensa, an Ontario biotechnology company specialized in the development and commercialization of chitosan biopolymers. Chitosan, mainly produced from the shells of crustaceans has unique properties making it useful for various applications among which: plant protection, food preservation, wound healing acceleration, drug delivery, antimicrobial substance, hypocholesterolemic soluble fiber and cosmetic ingredient.

> View full press release